Ao Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ao Guo has a total of 121 co-authors. Here are the top co-authors by number of shared publications:
- Zhutian Zeng
National Key Laboratory of Immune Response and Immunotherapy, Department of Oncology, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
35 shared publications - Daxing Gao
The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China 8 Department of General Surgery Hefei
34 shared publications - Fang Fang
Reproductive and Genetic Center, The First Affiliated Hospital of USTC, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230026, China
34 shared publications - He Huang
National Key Laboratory of Immune Response and Immunotherapy, Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Center for Advanced Interdisciplinary Science & Biomedicine IHM, Division of Life Sciences & Medicine, University of Science and Technology of China, Hefei, China
34 shared publications - Jiahao Yin
National Key Laboratory of Immune Response and Immunotherapy, Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Center for Advanced Interdisciplinary Science & Biomedicine IHM, Division of Life Sciences & Medicine, University of Science and Technology of China, Hefei, China
34 shared publications - Jialu Ma
National Key Laboratory of Immune Response and Immunotherapy, Department of General Surgery, The First Affiliated Hospital of University of Science and Technology of China, Center for Advanced Interdisciplinary Science & Biomedicine IHM, Division of Life Sciences & Medicine, University of Science and Technology of China, Hefei, China
34 shared publications
Latest Publications
- 29 September 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (19) , e72318
In vivo CRISPR Screening Reveals LBR as a Regulator of CD8 + T Cell Fate Decision
CD8 + T cells play an important role in anti‐infection and anti‐tumor immunity. Metabolic reprogramming has emerged as a critical regulator of T cell function, yet the roles of specific cholesterol‐associated proteins during T cell fate trajectories remain unclear. Here, using an in vivo CRISPR screen in CD8 + T cells during infection with a customized sgRNA library targeting key cholesterol metabolism‐associated proteins, we successfully identified several candidate targets, including the LBR (Lamin B Receptor). Lbr knockout significantly reduced the proportion and absolute number of short‐lived effector cells (SLECs), severely impairing effector responses, while concomitantly increasing the memory precursor population upon LCMV infection. Furthermore, transcriptomic analysis revealed that Lbr depletion markedly altered signaling pathways governing effector T cell differentiation. These findings reveal the role of LBR in modulating effector and memory T cell differentiation, suggesting it as a potential target for metabolic reprogramming to enhance T cell‐based immunotherapies.
- 29 September 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (19) , e72318
In vivo CRISPR Screening Reveals LBR as a Regulator of CD8 + T Cell Fate Decision
CD8 + T cells play an important role in anti‐infection and anti‐tumor immunity. Metabolic reprogramming has emerged as a critical regulator of T cell function, yet the roles of specific cholesterol‐associated proteins during T cell fate trajectories remain unclear. Here, using an in vivo CRISPR screen in CD8 + T cells during infection with a customized sgRNA library targeting key cholesterol metabolism‐associated proteins, we successfully identified several candidate targets, including the LBR (Lamin B Receptor). Lbr knockout significantly reduced the proportion and absolute number of short‐lived effector cells (SLECs), severely impairing effector responses, while concomitantly increasing the memory precursor population upon LCMV infection. Furthermore, transcriptomic analysis revealed that Lbr depletion markedly altered signaling pathways governing effector T cell differentiation. These findings reveal the role of LBR in modulating effector and memory T cell differentiation, suggesting it as a potential target for metabolic reprogramming to enhance T cell‐based immunotherapies.
- 24 June 2026
- Published by Springer Nature in Nature
- Vol. 655 (8123) , E5
Author Correction: cBAF complex components and MYC cooperate early in CD8+ T cell fate
- 24 June 2026
- Published by Springer Nature in Nature
- Vol. 655 (8123) , E5
Author Correction: cBAF complex components and MYC cooperate early in CD8+ T cell fate
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
Representative FACS dot plots for splenic analysis in the OVA-mRNA vaccine immunized mice
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
Representative FACS dot plots for splenic analysis in the OVA-mRNA vaccine immunized mice
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
HcGASK187N_L195R mRNA-LNP restrict tumor progression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S10 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
HcGASK187N_L195R mRNA-LNP restrict tumor progression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S13 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
CGAS mRNA-LNP activated splenic immune cells in the tumor model
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S13 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
CGAS mRNA-LNP activated splenic immune cells in the tumor model
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
Liver toxicity of cGAS mRNA-LNPs in tumor therapy
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
Liver toxicity of cGAS mRNA-LNPs in tumor therapy
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
CGAS mRNA-LNP drives a robust vaccine response with minimal toxicity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
CGAS mRNA-LNP drives a robust vaccine response with minimal toxicity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
CGAS mRNA-LNPs induce innate immune activation in human PBMC in vitro
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
CGAS mRNA-LNPs induce innate immune activation in human PBMC in vitro
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
Representative FACS dot plots for splenic analysis in the RBD protein vaccine immunized mice
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from cGAS mRNA–Based Immune Agonist Promotes Vaccine Responses and Antitumor Immunity
Representative FACS dot plots for splenic analysis in the RBD protein vaccine immunized mice